Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients

International Journal of Cancer

Volumn 115, Issue 4, 2005, Pages 545-555

  Yuan, Ang ^a   Yu, Chong Jen ^a   Shun, Chia Tung ^a   Luh, Kwen Tay ^a   Kuo, Sow Hsong ^a   Lee, Yung Chie ^a   Yang, Pan Chyr ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cancer cell; COX 2 mRNA; Lung cancer; Microvessel count; Prognosis; Real time quantitative RT PCR; Stromal cell; VEGF mRNA

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER STAGING; CELL INTERACTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STROMA CELL; SURVIVAL TIME;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18544388537     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20898     Document Type: Article

References (65)

1. Kune GA, Kune S, Wastson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1998;48:4399-404.
2. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
3. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shairo S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
4. Giardiello FM, Hamiltone SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhause GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
5. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
6. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
7. Taketo MM. Cyclooxygenase inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
8. Taketo MM. Cyclooxygenase inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-15.
9. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
10. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
11. Hershman JR. Prostaglandin synthase 2. Biochem Biophys Acta 1996;1299:125-40.
12. Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
13. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-92.
14. Perkins DJ, Kniss DA. Rapid and transient induction of cyclooxygenase 2 by epidermal growth factor in human amnion-derived WISH cells. Biochem J 1997;321:677-81.
15. Shen H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000;275:6628-35.
16. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta1 in human lung fibroblasts. Exp Cell Res 1998;241:222-9.
17. Perkins DJ, Kniss DA. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs. Prostaglandins 1997;54:727-43.
18. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer 2001;1:11-21.
19. Sano H, Kuwahito Y, Wilder RL. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1997;55:3785-9.
20. Ristimaki A, Honkanen N, Jankala H. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
21. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
22. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
23. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:5599-602.
24. Denkert C, Kobel M, Berger S, Sieger A, Leclere A, Trefzer U, Hauptmann S. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61:303-8.
25. Hwang D, Scollard D, Byrne J. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-560.
26. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-50.
27. 2 in human colon cancer cells. Cancer Res 1998;58:362-6.
28. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
29. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer. Cell 1998;93:705-16.
30. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
31. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641-9.
32. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-76.
33. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
34. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121:1339-47.
35. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-14.
36. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002;33:213-9.
37. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, Pairolero P, Trastek V, Jett J, Caporaso NE, Liotta LA, Hariis CC. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
38. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu SC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
39. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002;19:527-34.
40. Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World J Urol 2002;20:190-5.
41. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002;17:914-21.
42. Murata H, Kawano S, Tsuji S, Tsujii M, Sawaoka H, Kimrua Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-5.
43. Ferrandina G, Lauriola L, Zannoni GF, Distefano MG, Legge F, Salutari V, Gessi M, Maggiano N, Scambia G, Ranelletti FO. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002;87:1145-52.
44. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki KI, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
45. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki KI, Nakamura S, Ogawa M, Mitsudomi T, Surgiura T, Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
46. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor in a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
47. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-63.
48. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62.
49. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997;3:861-5.
50. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-8.
51. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-10.
52. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
53. Gibson UE, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR. Genome Res 1996;6:995-1001.
54. WHO. Histological typing of lung tumors. Am J Clin Pathol 1982;77:123-36.
55. Moutain CF. A new international staging system for lung cancer. Chest 1986;89:225s-33s.
56. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56.
57. Macchiarini P, Fontanini G, Hardin MJ, Squartinin F, Angelerti CA. Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:1120-4.
58. Glantz SA. Alternatives to analysis of variance and the t test based on ranks.In: Glantz SA, ed. Primer of biostatistics,3rd ed. New York: McGraw-Hill, 1992.320-71.
59. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1956;53:457-81.
60. Gullino PM. Prostaglandins and gangliosides of tumor microenvironment: their role in angiogenesis. Acta Oncol 1995;34:439-41.
61. 2 regulation of endothelial cell migration, angiogenesis and tumor metastasis. Biochem Biophys Res Commun 2000;267:245-51.
62. Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res 2000;275:9102-5.
63. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:1-9.
64. Chen JW, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729-37.
65. Edwards JG, Faux SP, Plummer SM, Abrams KR, Walker RA, Waller DA, O'Byrne KJ. Cycloxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857-62.